Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record.

Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

Open access
Burger, David, Van Der Heiden, Ilse, La Porte, Charles, Van Der Ende, Marchina, Groeneveld, Paul, Richter, Clemens, Koopmans, Peter, Kroon, Frank, Sprenger, Herman, Lindemans, Jan, Schenk, Paul, Van Schaik, Ron · 2006 · British Journal of Clinical Pharmacology

Abstract

Aims: To characterize the demographic and pharmacogenetic factors that influence interpatient variability in the plasma concentrations of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz. Methods: Data from all samples analyzed for efavirenz in our TDM service in 2002 and 2003 were reviewed. Information on gender, age, body weight, height, race, hormonal contraceptive use (in a subset of patients), and time between sampling and last intake was recorded. PCR‐restriction fragment length polymorphism analysis was performed to detect the cytochrome P450 2B6 (CYP2B6) C1459T variant (present in CYP2B6*6 and CYP2B6*7) which is associated with low CYP2B6 activity. Results: A total of 255 patients were included in this analysis. The median plasma efavirenz concentration was 2.50 (interquartile range: 1.85–3.55) mg l−1. Eight patients (3.1%) were considered to have a subtherapeutic plasma concentration (<1.0 mg l−1) and 48 (18.9%) a toxic efavirenz concentration (>4.0 mg l−1). Gender, time after last intake, and race were the only factors that were significantly related to plasma efavirenz concentration in a multivariate analysis. No influence was observed for body weight, hormonal contraceptive use, and the presence of the CYP2B6 C1459T polymorphism. Conclusions: Gender and race are important factors in determining interpatient variability in plasma efavirenz concentrations which were unaffected by the presence of the CYP2B6 C1459T polymorphism. Physicians should be particularly alert for signs of efavirenz‐induced toxicity in females and non‐Caucasian patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2005.02536.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 209

Metadata

Authors
Burger, D., Van Der Heiden, I., La Porte, C., Van Der Ende, M., Groeneveld, P., Richter, C., Koopmans, P., Kroon, F., Sprenger, H., Lindemans, J., Schenk, P., & Van Schaik, R.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2005-11-11
Volume
61
Issue
2
Pages
148-154
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2126546063
Cited by
209
References
0
FWCI
10.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. https://app.cochat.ai/papers/10.1111/j.1365-2125.2005.02536.x
The paper
Burger, D., Van Der Heiden, I., La Porte, C., Van Der Ende, M., Groeneveld, P., Richter, C., Koopmans, P., Kroon, F., Sprenger, H., Lindemans, J., Schenk, P., & Van Schaik, R. (2006). Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2005.02536.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.